BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

The third-generation tyrosine kinase inhibitor (TKI) ponatinib exerts a strong anti-neoplastic effect in all stages of chronic myeloid leukemia (CML) as well as in Philadelphia(Ph)-positive acute lymphoblastic leukemia (ALL). It is capable of suppressing the kinase activity of BCR-ABL1 carrying any